The value of multigene predictors of clinical outcome in breast cancer

An analysis of the evidence

Amalia M. Issa, Vivek S. Chaudhari, Gary Marchant

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: Multigene predictors are being used increasingly in early-stage breast cancer patients for prediction and prognosis. However, one consequence of the increased use of multigene predictors, and the heightened efforts toward their incorporation into routine clinical practice, is the potential for future malpractice litigation. It is, therefore, important to ascertain the strength of the evidence for using the different commercially available multigene predictor assays clinically. We evaluated the literature for evidence of clinical validity of four currently available gene signatures and to assess the influence of the 21-gene-expression assay on changes in treatment recommendations. Methods: A systematic search of the peer-reviewed literature from January 2002 to March 2014 for multigene predictor assays was carried out, and a meta-analysis was conducted. Results: The adjusted Cox hazard ratio average for studies that met the eligibility criteria was 3.538 (95% CI: 1.513-8.469). The 21-gene signature showed the highest stability in the estimation of likelihood of distant risk of recurrence. Using the recurrence scores resulted in changes in treatment recommendations in 31.8% of all patients in the studies. Conclusion: This study may provide insight about the use of multigene predictors in clinical practice for prediction and prognosis of breast cancer.

Original languageEnglish (US)
Pages (from-to)277-286
Number of pages10
JournalExpert Review of Molecular Diagnostics
Volume15
Issue number2
DOIs
StatePublished - Feb 1 2015

Fingerprint

Breast Neoplasms
Recurrence
Malpractice
Jurisprudence
Genes
Meta-Analysis
Gene Expression
Therapeutics

Keywords

  • breast cancer
  • Cox hazard ratios
  • gene-expression profiling
  • meta-analysis
  • multigene predictors
  • recurrence score

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pathology and Forensic Medicine

Cite this

The value of multigene predictors of clinical outcome in breast cancer : An analysis of the evidence. / Issa, Amalia M.; Chaudhari, Vivek S.; Marchant, Gary.

In: Expert Review of Molecular Diagnostics, Vol. 15, No. 2, 01.02.2015, p. 277-286.

Research output: Contribution to journalArticle

@article{8cdbec0bc0ec4e9683561137ca32c477,
title = "The value of multigene predictors of clinical outcome in breast cancer: An analysis of the evidence",
abstract = "Objective: Multigene predictors are being used increasingly in early-stage breast cancer patients for prediction and prognosis. However, one consequence of the increased use of multigene predictors, and the heightened efforts toward their incorporation into routine clinical practice, is the potential for future malpractice litigation. It is, therefore, important to ascertain the strength of the evidence for using the different commercially available multigene predictor assays clinically. We evaluated the literature for evidence of clinical validity of four currently available gene signatures and to assess the influence of the 21-gene-expression assay on changes in treatment recommendations. Methods: A systematic search of the peer-reviewed literature from January 2002 to March 2014 for multigene predictor assays was carried out, and a meta-analysis was conducted. Results: The adjusted Cox hazard ratio average for studies that met the eligibility criteria was 3.538 (95{\%} CI: 1.513-8.469). The 21-gene signature showed the highest stability in the estimation of likelihood of distant risk of recurrence. Using the recurrence scores resulted in changes in treatment recommendations in 31.8{\%} of all patients in the studies. Conclusion: This study may provide insight about the use of multigene predictors in clinical practice for prediction and prognosis of breast cancer.",
keywords = "breast cancer, Cox hazard ratios, gene-expression profiling, meta-analysis, multigene predictors, recurrence score",
author = "Issa, {Amalia M.} and Chaudhari, {Vivek S.} and Gary Marchant",
year = "2015",
month = "2",
day = "1",
doi = "10.1586/14737159.2015.983476",
language = "English (US)",
volume = "15",
pages = "277--286",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - The value of multigene predictors of clinical outcome in breast cancer

T2 - An analysis of the evidence

AU - Issa, Amalia M.

AU - Chaudhari, Vivek S.

AU - Marchant, Gary

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Objective: Multigene predictors are being used increasingly in early-stage breast cancer patients for prediction and prognosis. However, one consequence of the increased use of multigene predictors, and the heightened efforts toward their incorporation into routine clinical practice, is the potential for future malpractice litigation. It is, therefore, important to ascertain the strength of the evidence for using the different commercially available multigene predictor assays clinically. We evaluated the literature for evidence of clinical validity of four currently available gene signatures and to assess the influence of the 21-gene-expression assay on changes in treatment recommendations. Methods: A systematic search of the peer-reviewed literature from January 2002 to March 2014 for multigene predictor assays was carried out, and a meta-analysis was conducted. Results: The adjusted Cox hazard ratio average for studies that met the eligibility criteria was 3.538 (95% CI: 1.513-8.469). The 21-gene signature showed the highest stability in the estimation of likelihood of distant risk of recurrence. Using the recurrence scores resulted in changes in treatment recommendations in 31.8% of all patients in the studies. Conclusion: This study may provide insight about the use of multigene predictors in clinical practice for prediction and prognosis of breast cancer.

AB - Objective: Multigene predictors are being used increasingly in early-stage breast cancer patients for prediction and prognosis. However, one consequence of the increased use of multigene predictors, and the heightened efforts toward their incorporation into routine clinical practice, is the potential for future malpractice litigation. It is, therefore, important to ascertain the strength of the evidence for using the different commercially available multigene predictor assays clinically. We evaluated the literature for evidence of clinical validity of four currently available gene signatures and to assess the influence of the 21-gene-expression assay on changes in treatment recommendations. Methods: A systematic search of the peer-reviewed literature from January 2002 to March 2014 for multigene predictor assays was carried out, and a meta-analysis was conducted. Results: The adjusted Cox hazard ratio average for studies that met the eligibility criteria was 3.538 (95% CI: 1.513-8.469). The 21-gene signature showed the highest stability in the estimation of likelihood of distant risk of recurrence. Using the recurrence scores resulted in changes in treatment recommendations in 31.8% of all patients in the studies. Conclusion: This study may provide insight about the use of multigene predictors in clinical practice for prediction and prognosis of breast cancer.

KW - breast cancer

KW - Cox hazard ratios

KW - gene-expression profiling

KW - meta-analysis

KW - multigene predictors

KW - recurrence score

UR - http://www.scopus.com/inward/record.url?scp=84921326144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921326144&partnerID=8YFLogxK

U2 - 10.1586/14737159.2015.983476

DO - 10.1586/14737159.2015.983476

M3 - Article

VL - 15

SP - 277

EP - 286

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7159

IS - 2

ER -